NYSEMKT: PTHSPelthos Therapeutics Inc Stock
$16.19-0.31 (-1.88%)
Updated Jul 3, 2025
PTHS Price
$16.19
Fair Value Price
N/A
Market Cap
$10.68M
52 Week Low
$4.50
52 Week High
$38.00
P/E
-1.31x
P/B
-2.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.22
Operating Cash Flow
-$4M
Beta
1.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTHS's potential to beat the market
- PTHS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTHS
RankedUnranked of 468
RankedUnranked of 468
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $3.58 | A | |
| $46.15 | A |
Be the first to know about important PTHS news, forecast changes, insider trades & much more!
PTHS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTHS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTHS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTHS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PTHS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PTHS due diligence checks available for Premium users.
Valuation
PTHS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.31x
Industry
-154.26x
Market
30.96x
PTHS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.54x
Industry
4.54x
PTHS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
PTHS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$911.2k
Liabilities
$5.1M
Debt to equity
-1.22
PTHS's short-term liabilities ($5.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTHS's short-term assets ($911.18k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTHS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTHS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$632.1k
Investing
$0.0
Financing
$250.0k
PTHS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTHS vs Biotech Stocks
Pelthos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.